Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions

During the last 15 years we have witnessed an unprecedented expansion in the drugs developed to target human epidermal growth factor receptor-2 (HER-2) positive breast cancer. Trastuzumab, pertuzumab, ado-trastuzumab emtansine and lapatinib are currently food and drug administration (FDA)-approved f...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Recondo, Gonzalo Jr, Dìaz Canton, Enrique, de la Vega, Màximo, Greco, Martin, Recondo, Gonzalo Sr, Valsecchi, Matias E
Format: Artigo
Jezik:Inglês
Izdano: Baishideng Publishing Group Inc 2014
Teme:
Topic Highlight
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4127614/
https://ncbi.nlm.nih.gov/pubmed/25114858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5306/wjco.v5.i3.440
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items